Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Global X NASDAQ 100 Covered Call ETFTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Global X NASDAQ 100 Covered Call ETF vs Vir Biotechnology Inc. Common Stock — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.63 (market cap $8.54B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.76B). The key difference: Global X NASDAQ 100 Covered Call ETF is far larger — about 4.9× Vir Biotechnology Inc. Common Stock's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Vir Biotechnology Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

QYLDVIR
Market Cap
$8.54B$1.76B
Volume
2,727,5782,764,948
Sector
Income / Options OverlayHealth
52-Week High
$18.69$11.78
52-Week Low
$16.70$5.12
Typical Hold Time
51 Days0 Days
Enterprise Value
—$1.32B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X NASDAQ 100 Covered Call ETF

QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF maintains its covered call strategy on the Nasdaq 100, generating consistent monthly dividends of $0.18 per share. Technical indicators show mixed signals with moving averages bullish but oscillators bearish, while RSI levels above 75 suggest overbought conditions. Recent news highlights concerns about principal erosion despite the attractive yield.

The outlook remains cautious as QYLD's high yield comes with capped upside potential during market rallies. While providing reliable monthly income, the strategy sacrifices long-term capital appreciation. Key risks include declining option premiums and tax treatment uncertainties that could impact total returns for income-focused investors.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

QYLD
62% Buy38% Sell
Avg holding period · 51 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Global X NASDAQ 100 Covered Call ETF

QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.

Read more on QYLD →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →